Company Overview: Eli Lilly and Company
Company Overview: Eli Lilly and Company
Eli Lilly Company代写 Eli Lilly and Company is a multinational pharmaceutical corporation. It is located in Indianapolis in Indiana.
Company Description Eli Lilly Company代写**成品
Eli Lilly and Company is a multinational pharmaceutical corporation. It is located in Indianapolis in Indiana. It was established in 1876 and operate in more than 125 countries globally (Lilly Home, n.d). It operates in the pharmaceutical industry. The company develops, manufactures, distributes, and markets pharmaceutical products for humans and animals. Among other companies that Eli Lilly and Company compete with include Pfizer, Merck, gsk and Amgen, Vivus, MannKind Corporation, and more.
Accounting Standard Eli Lilly Company代写
The company uses Generally Accepted Accounting Principles (GAAP) in its financial reporting. The use of GAAP standards is for understandability of its financial statements and reports by the international stakeholders. The report states its application of GAAP as the primary reporting standard (Eli Lilly and Company, 2018). The company applied GAAP as it focuses on the conventional methodology of using literature to explain the various accounting interpretations and achievements.Eli Lilly Company代写**成品
The accounting statement includes only those disclosures allowed by the GAAPs like deduction of expenses and depreciation to get net profit. The standard also allows the company to make estimations and assumptions that may affect the reported assets and liabilities, as well as other disclosures. Contrary to the International Financial Reporting Standard, GAAP is ruled based by which the disclosure follows a specific structure and items for inclusion in financial statement and balance sheet.
Press Release Summary Eli Lilly Company代写
In the year ended 2018, the company had numerous press releases all focusing on various announcements from new products, acquisitions, investments made, dividend payments, and other programs in the pipeline in the company’s strategic plan (Lilly Media, 2018). The press release for the year ended 2018 focused on guidance and reviews of financial performance, and an overview of investment opportunities. The statement was given at the investment community meeting in Indianapolis.Eli Lilly Company代写**成品
The statement discusses the expected revenue in 2019, which was projected to be $25.3 billion and $25.8 billion.
The predicted opportunities were to be driven by sales volume from the new medicines, including Trulicity, Taltz, Basaglar, Jardiance, Verzenio, Cyramza, Olumiant, and Lartruvo as well as Emgality. The earning per share was projected to range between $5.52 to $5.62 or $5.90 to $6.00 on a reported basis and non-GAAP basis, respectively. Also, with the launch of over ten new products over the past five years, it was an indication of future growth in 2019. As such, it was expected to achieve six percent compound revenue by 2020 with much growth expected from the human pharmaceutical products.Eli Lilly Company代写**成品
The pipeline growth opportunities for the company came from five therapy areas, including oncology, pain, neurodegeneration, immunology, and diabetes. The company hoped to make the opportunities have positive financial outlook. Besides, the prospective investment opportunities will not only add value to the company’s revenue but also help in growth and diversification in the global market.Eli Lilly Company代写**成品
The above press release is essential in communication and informing the stakeholders, particularly the investors of the general performance and prospects of the company. The release seeks to give hope of investment growth for its shareholders. It also clarifies the issues about running on the affairs and strategic plans of the company. The company is performing well, and it has a trend of higher growth in the future. This is owing to the investment opportunities identified in the press releases.
The essay provides an essential exposition about Eli Lilly and Company. Eli Lilly Company代写
It evaluates the financial position of the company and its prospective future performance in the pharmaceutical industry. The financial report was forward-looking and hence reported on the company’s performance based on going concern. According to the profits for the year 2018, the company has future financial stability. The investment prospects are an indication that the company will continue to maintain its global competitiveness in the pharmaceutical industry.Eli Lilly Company代写**成品
References Eli Lilly Company代写
Lilly Home. (n.d). About us. Retrieved from https://www.lilly.com/who-we-are
Eli Lilly and Company. (2018). Eli Lilly and Company 2018 financial report, a notice of 2019 annual meeting and proxy statement (pp. 1-186). Indianapolis. Retrieved from https://investor.lilly.com/static-files/9a86e5d8-705c-4315-a3b2-56bfc208d1ca
Lilly Media. (2018). Lilly announces financial guidance, reviews commercial performance, and highlights promising pipeline opportunities at an investment community meeting. Retrieved from http://lilly.mediaroom.com/index.php?s=9042&item=137858